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A case of Hodgkin lymphoma located in the rectum of a patient with ulcerative colitis is described. The patient was
a 44 year old male treated with thiopurines for ulcerative colitis for ten years. He was admitted with malaise, weight
loss and abdominal pain. Endoscopy revealed a large ulcerative lesion involving the rectum and distal part of the
sigmoid colon. Although it macroscopically resembled a rectal cancer, repeated biopsies did not reveal any
malignancy. In order to resolve the symptoms of stenosis and to get the final diagnosis a recto-sigmoid resection was
performed. Pathologic examination revealed nodular sclerosis classical Hodgkin lymphoma, positive for Epstein Barr
Virus. Subsequent examination revealed disseminated disease involving the pelvic wall, liver, and bone marrow. The
patient is currently receiving chemotherapeutic treatment, and follow-up shows disease remission.
Hodgkin lymphoma associated with immunosuppressive therapy is rare. However, patients with ulcerative colitis
receiving such treatment are at increased risk of lymphoproliferative disordes, potentially due to loss of
immunosurveillance and presence of oncogenic viruses (i.e. Epstein-Barr virus).
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Hodgkin lymphoma (HL) is a relatively rare disease with
an estimated 9.190 new cases in the United States in
2014 [1].Primary extranodal lymphomas of the gastro-
intestinal tract are rare. Lymphomas only account for
0.2-0.6% of large bowel malignancies [2] and primary
HL involving the gastrointestinal tract is only reported
in a limited number of case reports [3-5].
Most patients with HL do not have a history of
immunodeficiency, but a small subset of cases arise in
patients with acquired immunodeficiency (e.g. patients
suffering from human immunodeficiency virus) and pa-
tients receiving immunomodulatory therapeutic agents
(e.g. patients who have received organ transplants) [6,7].
In this report, a rare case of an advanced stage HL
diagnosed in the rectum and sigmoid colon of patient
with ulcerative colitis is presented.* Correspondence: simon.rasmussen@rn.dk
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A 44 year old male presented in 2004 with a history of
abdominal pain, intermittent diarrhoea, and rectal
bleeding. A colonoscopy was performed, and severe in-
flammation was found in the recto-sigmoid mucosa.
The clinical, endoscopic, and pathologic findings were
consistent with ulcerative colitis. Initial medical treatment
was Azathioprine (50 mg, three times a day), Prednisolone
(50 mg, one time a day), and 5-aminosalicylic acid
(800 mg, three times a day). The patient was continually
treated with Azathioprine through ten years. On multiple
occasions, he was admitted with exacerbations, and
treated with Prednisolone and 5-aminosalicylic acid.
In 2014, the patient experienced malaise, weight loss,
night sweat, and intermittent fever for three to four
months before admission. Sigmoideoscopy showed a
large ulcerative lesion obstructing the recto-sigmoid
colon (Figure 1). Multiple biopsies did not reveal malig-
nancy but macroscopically it was believed to be a colorec-
tal cancer. In order to resolve the symptoms of stenosis
and to reveal the final diagnosis, a partial recto-sigmoid
resection was performed. The workup of the patient wasMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Endoscopic images of the rectum. A) Large ulcerative lesion located in the lower center of the image. B) Large ulcerative lesion located
in the left side of the image.
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embolism, for which the patient needed treatment with
low molecular weight heparin.
Pathology
The recto-sigmoid resection specimen showed a deep
ulcer measuring 4 × 5 cm with relatively sharp edges
(Figure 2A). Corresponding to the ulcer there was a
tumorous swelling of the serosa, which was dark and
granulated.
Histological evaluation of the ulcer revealed nodular
sclerosis classical HL, with Hodgkin and Reed-Sternberg
cells surrounded by nodular infiltrates of lymphocytes,
plasma cells and eosinofilic granulocytes, in the mus-
cularis propria and subserosa (Figure 2C). Immunohis-
tochemically, the Hodgkin and Reed-Sternberg cellsFigure 2 Resection specimens. A) Gross section image showing the opene
wall showing the transition from unaffected mucosa to ulcer (notice the no
C) High power image of a nodule showing Hodgkin and Reed-Sternberg c
Hodgkin and Reed-Sternberg cells positive for CD15. E) High power image
power image demonstrating Epstein-Barr virus by positive fluorescence in
RNA’s (EBER).stained positive for CD15, CD30, PAX5 (weak), and fluor-
escence in situ hybridization for EBER (Epstein–Barr
virus-encoded small RNAs) was positive (Figure 2D-F).
At the same time focal extranodal, but no nodal, in-
volvement of the sigmoid and rectal serosa, the sigmoid
mesocolon and the peritoneum of the urinary bladder
was demonstrated histologically.
Postoperative course and treatment
Postoperative positron emission tomography-computed
tomography (PET-CT), revealed advanced stage disease,
with increased metabolic activity in the liver, pelvic mus-
cles, and bone marrow in the thoracic region (Figure 3).
Four months after the surgery, the patient had received
six of twelve rounds of chemotherapeutic treatment, with
Adriamycin, Bleomycin, Vinblastine, and Dacarbazine.d sigmoid colon with a deep ulcer. B) Low power image of the gut
dules and the marked fibrosis in the deep parts of the gut wall).
ells in an inflammatory environment. D) High power image showing
showing Hodgkin and Reed-Sternberg cells positive for CD30. F) High
situ hybridization reaction for Epstein-Barr virus encoded small
Figure 3 Positron emission tomography-computed tomography images. A) Transverse image showing increased metabolic activity in the sigmoid
colon and pelvic wall. B) Saggittal image showing the extent of the tumor proximally in the sigmoid colon including increased metabolic activity in
the pelvic wall and para-aortic lymph nodes. C) 3D image showing the extent of the disease, with increased metabolic activity in para-aortic lymph
nodes, left axillary lymph nodes, bone marrow (T1 and T6), liver, spleen, and pelvic wall. Iliac lymph nodes are regarded as reactive.
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remission.
Discussion
Patients with ulcerative colitis are at increased cancer
risk, especially with regard to colorectal adenocarcin-
oma, with annual incidence rates being elevated by close
to 30%, compared to patients without inflammatory
bowel disease (IBD) [8]. However, a recent study was
not able to reproduce this increased risk when stratifying
for treatment with immunomodulating agents (including
thiopurines) [9].Whether the risk of malignant lymphomain patients with IBD is increased is controversial. Recent
studies have found no, or only a marginally elevated risk
of lymphoproliferative disorders [9-11]. However, it has
been shown that the risk of developing lymphoprolifera-
tive disorders is increased in IBD as well as other patients
receiving thiopurines as treatment (HR, 5.28; 95% CI,
2.01-13.9) [12]. An increased incidence of lymphomas in
IBD patients could, therefore, be attributed to treatment
with immunosuppressive drugs. A study on patients with
rheumatoid arthritis showed that high inflammatory ac-
tivity was a risk factor for lymphoma development (OR,
5.8; 95% CI, 3.1-213) [13], and it has been speculated
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tive colitis [14].
HL attributed to treatment with immunosuppressive
drugs is very rare and only described in case studies.
These cases are primarily described in patients with
rheumatoid arthritis and Crohn’s disease, promoting IBD
patients treated with immunosuppressants as a group a
higher risk [15]. The majority of cases described were
also positive for Epstein-Barr virus promoting oncogenic
viral infection as an additional risk factor [15].
The diagnosis of extranodal HL can be a challenge.
Classical HL is based on the identification of mononu-
cleated Hodgkin cells and multinucleated giant cells
termed Reed-Sternberg cells, within an inflammatory
environment [16]. The Hodgkin and Reed-Sternberg
cells are however, vastly outnumbered by reactive in-
flammatory cells, which constitute from 90–99.9% of the
tumour mass [16].
In the present case, the initial biopsies only showed
chronic ulcer, while surgical resection provided material
from the deeper parts of the gut wall, which revealed the
final diagnosis. The preoperative biopsies were reviewed
with the disease in mind, but no Reed-Sternberg cells
could be distinguished.
Conclusions
The patient had received treatment with both thiopurines
(continually) and 5-aminosalicylic acid (intermittently)
through ten years. Special attention should be given to
such patients, when they present symptoms that are not
characteristic of their known inflammatory disease, as
their risk of lymphoproliferative disorders is increased.
Even though extranodal presentation of HL is a rare
entity, the possibility should be kept in mind, as survival
relies on early and efficient treatment.
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